Chimeric Fc receptors identify immunoglobulin-binding regions in human FcγRII and FcϵRI

FcγRII and Fc?RI are functionally distinct cell surface receptors for immunoglobulin (Ig); FcγRII binds IgG with low affinity, whereas Fc?RI binds IgE with high affinity, yet they are homologous in structure and sequence having extracellular regions containing two Ig-like domains with 38% amino acid identity. Chimeric receptors derived from human FcγRII and FcγRI were produced by exchanging homologous regions of the two receptors to define binding region(s) for IgG in FcγRII and IgE in Fc?RI. Firstly, a chimeric form of the Fc?RI α chain was produced by replacing the transmembrane region and cytoplasmic tail with that of FcγRII. This mutant α chain could be expressed on the cell surface independently of associated β and γ subunits, and retained high-affinity IgE binding, indicating that the extracellular region of the FcγRI α chain is sufficient for high-affinity IgE binding. Secondly, to identify the role of the individual domains in Fc binding of both FcγRII and FcγRI, chimeric receptors were generated by exchanging the first extracellular domains between FcγRII and the α chain mutant and used to demonstrate that the second extracellular domain of both receptors contains region(s) directly involved in Ig binding. Additional chimeric receptors were constructed to localize the Ig interactive regions in domain two of FcγRII and FcγRI; these identified a single region of IgG binding in FcγRII located between residues Ser¹³⁶ to Val¹⁶⁹, and at least three independent IgE binding regions in the FcγRI α chain, between residues Trp⁸⁷ to Lys¹²⁸, Tyr¹²⁹ to Asp¹⁴⁵, and Ser¹⁴⁶ to Val¹⁶⁹.     

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials

During the past 25 years, 24 randomized trials of intravenous(IV) fibrinolytic treatment have been reported, involving atotal of some 6000 patients in the acute phase of myocardialinfarction. Most tested IV streptokinase (SK), but a few testedIV urokinase (UK). In the past 2 or 3 years numerous small randomizedtrials of intracoronary (IC) SK have been started, 9 of which,involving a total of about 1000 such patients have been reported.Because all of these IV and IC trials were small (the largestincluding only 747 patients), their separate results appearcontradictory and unreliable. But, an overview of the data fromthese trials indicates that IV treatment produces a highly significant(22%±5%, (P<0.001) reduction in the odds of death,an even larger reduction in the odds of reinfarction, and anabsolute frequency of serious adverse effects to set againstthis that is much smaller than the absolute mortality reduction.The apparent size of the mortality reduction in the IV trialswas similar whether anticoagulants were compulsory or optional,whether treatment was in a coronary cure unit or an ordinaryward and, surprisingly, whether treatment began early ( <6h from onset of symptoms) or late (generally 12–24 h).In addition, there was no evidence that UK was more effectivethan the less expensive SK, or that, despite their technicalcomplexity, the new IC regimes were more effective than theold IV regimes. Even the IV schedules that have been studied in randomized trialswere, however, quite complex, and the IC schedules were farmore so. Perhaps partly because of this, none of them is widelyused. If so, then some much simpler, and hence more widely practicable,IV SK regimes should be developed and tested. For example, asimple one hour high-dose IV SK infusion, without anticoagulation,will successfully convert virtually all of the available plasminogeninto plasmin. But, it may be several years before the net effectson mortality of any more widely practicable IV SK regimes canbe agreed unless many of the hospitals that do not wish routinelyto use IC regimes or the complex previous IV regimes will collaboratein multicentre randomized trials that can, if necessary, continuerapid intake until some tens of thousands of patients have beenrandomized, and some thousands of deaths have been observedamong the control and treated patients. The same, of course,may be true for any other fibrinolytic regimes (e.g. infusionof tissue plasminogen activator) if their net effects on mortalityare comparable to those of IV SK.     

Experimental neurotoxicity of the anorectic fenfluramine

Summary Fenfluramine, an amphophilic compound which is a halogenated derivative of amphetamine, is still used as an anorectic agent for weight reduction, as it acts on the satiety center of the hypothalamus. Holtzman strain rats aged 6 days were daily injected s.c. fenfluramine hydrochloride at the dose of 75 mg/kg body weight. The animals were killed at different time intervals between days 7 and 40, and different parts of the brain were examined by light and electron microscopy. About half of the animals showed intralysosomal membrano-cytoplasmic bodies in the oligodendroglia, neurons, and neuropil, maximally in the animals receiving 8–19 injections. They were seen as concentrically arranged, single-layered lamellae; small dense bodies; or larger heterogeneous bodies. The mechanism of production of such inclusions could be the formation of complexes of this amphophilic compound with tissue phospholipids, or some enzyme-inhibiting action. A marked prominence of dark cells, predominantly oligodendroglia, was also noticed in the brains of experimental animals. Some of these cells appeared to be dark neurons, probably resulting from the serotonin-depleting effect of fenfluramine. A few dark cells were identified as resting microglial cells, while macrophagic reactive microglia were detected in the brains of very young animals. Fenfluramine appears to provide a model for studying neuroglial reactions.Paper presented at the Erwin Riesch symposium on Lysosomal Disorders of the Nervous System, Berlin (Convenor, Prof. Cervos-Navarro); and as poster-talk at the 9th International Congress of Neuropathology, Vienna, September 1982     

2015—2019年北京市食源性致泻大肠埃希氏菌感染病例流行特征分析

目的分析2015—2019年北京市食源性致泻大肠埃希氏菌(diarrheagenic Escherichia coli,DEC)感染病例的流行病学特征和发病规律,为制定相应的防控策略与措施提供科学依据。方法收集2015—2019年北京市36家食源性疾病主动监测医院腹泻病例的粪便或肛拭子标本及其个人信息,采用χ^(2)检验对率或构成比进行比较。结果共收集27619份病例标本,其中有2485份为DEC阳性病例,检出率为9.00%,不同分型中肠产毒性大肠埃希菌检出率最高,为3.10%,其次为肠聚集性大肠埃希菌,检出率为3.02%。不同年龄组DEC检出率差异有统计学意义(χ^(2)=32.923,P<0.001),20~39岁年龄组DEC检出率最高,为9.81%,40~59岁年龄组感染肠产毒性大肠埃希菌高于其他年龄组,0~5岁年龄组肠致病性大肠埃希菌的检出率最高。时间分布上,第三季度为高发期,不同季度间DEC检出率差异有统计学意义(χ^(2)=606.032,P<0.001)。空间分布上,远郊的DEC检出率最高,且城区、近郊和远郊的DEC检出率差异有统计学意义(χ^(2)=28.034,P<0.001),肠产毒性大肠埃希菌的检出主要分布在城区和近郊,肠聚集性大肠埃希菌主要分布在远郊。结论2015—2019年北京市食源性DEC的检出率呈逐年上升趋势,应在夏秋高发季节针对重点人群积极开展防控工作。     

2018—2020年徐州市食源性疾病监测分析

目的 分析徐州市2018—2020年食源性疾病哨点医院主动监测结果,了解该地区食源性疾病流行特征。方法 收集2018—2020年徐州市食源性疾病哨点医院监测的病例信息,并对部分病例的粪便样本进行病原学检测。结果 3年共监测食源性疾病病例7 548例,其中25～45岁年龄组占比最高(26.81%);6—9月为发病高峰;肉与肉制品(20.72%)为主要的可疑暴露食品;可疑食物进食场所主要为家庭(80.49%);农民(26.75%)和散居儿童(24.95%)病例构成比较高。共采集1 835份腹泻病例粪便样本,其中诺如病毒检出率最高为(4.69%)。结论 徐州市食源性疾病高发期为6—9月,具有明显的季节性,好发于家庭,肉与肉制品为主要暴露食品,感染患者集中在>25～45岁年龄组,诺如病毒感染率较高。     

补肾益智方治疗阿尔兹海默病的研究进展

阿尔茨海默病（AD）是最常见的痴呆形式,目前缺少疾病修饰性的治疗药物。中医理论认为肾精亏虚是AD发生发展的内在机制,补肾益精是中医治疗AD的基本原则,贯穿AD治疗的始终。补肾益智方是治疗AD的临床经验方。补肾益智方治疗AD已有大量文献报道,但补肾益智方缺乏临床应用安全性评价,同时其基础研究薄弱,有效成分不明、多靶点作用机制不清。为阐明补肾益智方多成分、多靶点、多途径治疗AD的作用机制,该文综述了补肾益智方治疗AD的研究进展。进一步收集了16个基于高效液相色谱指纹图谱的补肾益智方主要化学成分,并对其成药性与安全性进行评价。利用基于AD重要病理生理学过程的网络药理学与文献综述相结合的方法,深入分析了补肾益智方靶向胆碱能系统、AD神经病理学特征的有效成分及可能机制。该研究为AD对症治疗、疾病修饰性治疗的药物研发提供了一系列有潜力的先导化合物,并为深入拓展补肾益智方的临床应用提供了理论依据。     

一种复合微生物菌肥对穿心莲生长、品质及土壤性质的影响

目的：研究一种微生物复合菌肥对穿心莲生长、品质及土壤性质的影响,旨在为穿心莲栽培生产中微生物复合菌肥的应用提供依据。方法：通过盆栽的共5个处理试验,CK（不施肥）组、A处理（施化肥）组、B处理（施微生物菌肥,施用量为2.5 g·kg-1土）组、C处理（施微生物菌肥,施用量为7.5 g·kg-1土）组、D处理（施微生物菌肥,施用量为12.5 g·kg-1土）组,研究一种复合微生物菌肥对穿心莲的农艺性状、有效成分含量及根际土壤细菌、放线菌、真菌的数量和土壤理化性质的影响。结果：施加一定量的复合微生物菌肥,穿心莲的株高、叶片数、叶面积、地上部、地下部鲜重较CK组和A处理组显著升高,不同生长期有差异。复合微生物菌肥对穿心莲内酯、脱水穿心莲内酯、新穿心莲内酯及14-去氧穿心莲内酯含量影响有差异,与CK组、A处理组比较,C处理组的穿心莲内酯分别明显升高26.13%、13.23%(P<0.05);新穿心莲内酯的含量随微生物菌肥施加量的增加而增加,在D处理组下的效应最显著,与CK组、A处理组比较,分别明显升高9.06%、50.33%(P<0.05);B处理组的14-去氧穿心莲内酯较A处理组...     

杜仲及其有效成分治疗膝骨关节炎的作用机制研究现状

膝骨关节炎（KOA）是中老年常见的退行性关节疾病,发病率随着人口老龄化程度加深及肥胖人群增加而不断增加,严重影响患者健康及日常生活。目前采用的非甾体类抗炎药、软骨保护类药物、阿片类镇痛药等对症治疗手段作用有限,且药物不良反应明显。杜仲是治疗KOA常用且有效的中药之一,但其作用机制和药效物质基础尚未明确,限制了其在临床更为广泛的运用。杜仲在KOA治疗领域的有效成分主要为环烯醚萜类（京尼平苷、杜仲苷/桃叶珊瑚苷）、木脂素类（松脂醇二葡萄糖苷）、黄酮类（槲皮素、紫云英苷、黄芩素、金丝桃苷、山柰酚）、苯丙素类（绿原酸）、杜仲多糖等化合物,他们主要通过丝裂原活化蛋白激酶、核转录因子-κB、磷脂酰肌醇3-激酶/蛋白激酶B及等Janus激酶1/信号转导和转录激活因子3等信号通路,来调节炎性因子水平、抗氧化应激反应、保护软骨细胞、平衡细胞外基质合成与降解等,控制KOA病情进展。该文对杜仲及其有效成分在KOA治疗方面的作用机制进行了综述,以期为KOA新药研发提供理论依据。     

中药调控膝骨关节炎相关信号通路的研究进展

随着中医药对膝骨关节炎（KOA）研究的不断深入,现代学者发现诸多中药可从分子层面干预信号通路延缓膝骨关节炎的进展。文中所述中药及其活性成分在干预膝骨关节炎的机制中与信号通路有着密切关系。中药及有效成分可在不同信号通路的传导下调控相应的靶向分子水平,抑制软骨炎性因子、细胞凋亡、软骨基质降解及促进软骨细胞自噬,以达到减轻滑膜炎性水肿和延缓软骨退变的目的。现对国内外中药干预KOA的研究进行系统性总结：黄芩素等可通过阻断磷脂酰肌醇3-激酶/蛋白激酶B（PI3K/Akt）信号通路,减少软骨细胞炎性因子、凋亡及促进自噬;山茱萸新苷Ⅰ等成分降低Janus激酶2/信号转导和转录激活因子3（JAK2/STAT3）通路磷酸化活性改善滑膜炎症、延缓软骨基质退变;丹酚酸A等中药活性成分可通过抑制核转录因子-κB（NF-κB）通路磷酸化,减轻炎症与软骨基质降解;大黄素等有效成分可降低Wnt/β-连环蛋白（Wnt/β-catenin）通路活性,抑制胶原蛋白与蛋白多糖分解;肉豆蔻苷等通过阻断p38丝裂原活化蛋白激酶（p38 MAPK）信号传导,抑制细胞凋亡;木通皂苷D等可增强核因子E₂相关因子2/血红素加氧酶1（Nrf2/HO-1）通路活性,抑制软骨细胞氧化应激;牛膝总皂苷等通过增强转化生长因子-β（TGF-β）/Smad信号传导,减少软骨基质降解;藏红花素通过激发河马/Yes相关蛋白（Hippo/YAP）活性抑制软骨炎症与凋亡因子增加;川芎嗪阻断Notch通路改善软骨细胞形态与异常;齐墩果酸等通过发挥雌激素信号通路,减轻软骨基质破坏与退变。以上总结旨在为今后开展KOA临床与实验研究提供借鉴。     

儿童医院重点部门耐碳青霉烯类革兰阴性杆菌主动筛查结合集中安置干预效果评价

 目的 对耐碳青霉烯类革兰阴性杆菌（CR-GNB）进行主动筛查,结合筛查结果对患者进行集中安置,评价干预措施的效果,为CR-GNB医院感染防控提供科学依据。方法 选取2017年1月—2018年12月入住某儿科医院重点部门［新生儿、新生儿重症监护病房（NICU）、儿童重症监护病房（PICU）、血液科］患者为研究对象,并对所有患者进行医院感染实时监测。2017年对住院患者入院后48 h及住院期间每周进行一次CR-GNB主动筛查（咽拭子和肛拭子）,2018年1月开始对主动筛查及临床送检CR-GNB阳性患者开展集中安置措施,比较CR-GNB主动筛查率和定植率、集中安置率以及医院感染率的变化。结果 2018年重点部门咽拭子和肛试子CR-GNB主动筛查率较2017年增加（P<0.05）。新生儿室集中安置率最高（97.8%）,其次为NICU（88.9%）,PICU集中安置率最低（47.7%）。2018年重点部门CR-GNB定植率在住院3、7 d后呈下降趋势（P<0.05）。2018年CR-GNB医院感染率较2017年有所下降（P<0.05）,其中新生儿室和NICU患者耐碳青霉烯类肠杆菌目细菌（CRE）医院感染率下降明显,PICU患者耐碳青霉烯类鲍曼不动杆菌（CRAB）和耐碳青霉烯铜绿假单胞菌（CRPA）医院感染率下降明显。CR-GNB主动筛查定植菌和CR-GNB医院感染病原菌均以耐碳青霉烯类肺炎克雷伯菌（CRKP）为主（44.0% VS 51.7%）。结论 CR-GNB主动筛查结合患者集中安置干预措施能够降低CR-GNB定植率,并有效降低CR-GNB医院感染率。